- March 2, 2021
- Category: Healthcare and LifeSciences, Medical Device and Equipment
Global Neuromodulation market Size study, by Technology (Internal neuromodulation, External neuromodulation), by Application (Parkinson’s disease, Epilepsy, Depression, Dystonia, Pain Management, Others), and Regional Forecasts 2020-2027
Chapter 1. Executive Summary 1.1. Market Snapshot 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion) 1.2.1. Neuromodulation Market, by Technology, 2018-2027 (USD Billion) 1.2.2. Neuromodulation Market, by Application, 2018-2027 (USD Billion) 1.2.3. Neuromodulation Market, By Region, 2018-2027 (USD Billion) 1.3. Key Trends 1.4. Estimation Methodology 1.5. Research Assumption Chapter 2. Global Neuromodulation Market Definition and Scope 2.1. Objective of the Study 2.2. Market Definition & Scope 2.2.1. Scope of the Study 2.2.2. Industry Evolution 2.3. Years Considered for the Study 2.4. Currency Conversion Rates Chapter 3. Global Neuromodulation Market Dynamics 3.1. Neuromodulation Market Impact Analysis (2018-2027) 3.1.1. Market Drivers 3.1.2. Market Challenges 3.1.3. Market Opportunities Chapter 4. Global Neuromodulation Market Industry Analysis 4.1. Porter’s 5 Force Model 4.1.1. Bargaining Power of Suppliers 4.1.2. Bargaining Power of Buyers 4.1.3. Threat of New Entrants 4.1.4. Threat of Substitutes 4.1.5. Competitive Rivalry 4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2027) 4.2. PEST Analysis 4.2.1. Political 4.2.2. Economic 4.2.3. Social 4.2.4. Technological 4.3. Investment Adoption Model 4.4. Analyst Recommendation & Conclusion Chapter 5. Global Neuromodulation Market, by Technology 5.1. Market Snapshot 5.2. Global Neuromodulation Market by Source, Performance - Potential Analysis 5.3. Global Neuromodulation Market Estimates & Forecasts by Technology 2018-2027 (USD Billion) 5.4. Neuromodulation Market, Sub Segment Analysis 5.4.1. Internal Neuromodulation 5.4.2. External Neuromodulation Chapter 6. Global Neuromodulation Market, by Application 6.1. Market Snapshot 6.2. Global Neuromodulation Market by Source, Performance - Potential Analysis 6.3. Global Neuromodulation Market Estimates & Forecasts by Application 2018-2027 (USD Billion) 6.4. Neuromodulation Market, Sub Segment Analysis 6.4.1. Parkinson’s Disease 6.4.2. Epilepsy 6.4.3. Depression 6.4.4. Dystonia 6.4.5. Pain Management 6.4.6. Other Chapter 7. Global Neuromodulation Market, Regional Analysis 7.1. Neuromodulation Market, Regional Market Snapshot 7.2. North America Neuromodulation Market 7.2.1. U.S. Neuromodulation Market 22.214.171.124. Technology breakdown estimates & forecasts, 2018-2027 126.96.36.199. Application breakdown estimates & forecasts, 2018-2027 7.2.2. Canada Neuromodulation Market 7.3. Europe Neuromodulation Market Snapshot 7.3.1. U.K. Neuromodulation Market 7.3.2. Germany Neuromodulation Market 7.3.3. France Neuromodulation Market 7.3.4. Spain Neuromodulation Market 7.3.5. Italy Neuromodulation Market 7.3.6. Rest of Europe Neuromodulation Market 7.4. Asia-Pacific Neuromodulation Market Snapshot 7.4.1. China Neuromodulation Market 7.4.2. India Neuromodulation Market 7.4.3. Japan Neuromodulation Market 7.4.4. Australia Neuromodulation Market 7.5. Latin America Neuromodulation Market Snapshot 7.5.1. Brazil Neuromodulation Market 7.5.2. Mexico Neuromodulation Market 7.6. Rest of The World Neuromodulation Market Chapter 8. Competitive Intelligence 8.1. Top Market Strategies 8.2. Company Profile 8.2.1. Abbott Laboratories 188.8.131.52. Key Information 184.108.40.206. Overview 220.127.116.11. Financial (Subject to Data Availability) 18.104.22.168. Product Summary 22.214.171.124. Recent Developments 8.2.2. Boston Scientific Corporation 8.2.3. Medtronic PLC 8.2.4. Nevro Corporation 8.2.5. Neuropace Inc. 8.2.6. Neurosigma Inc. 8.2.7. Neuronetics Inc 8.2.8. LivaNova PLC 8.2.9. Nuvectra 8.2.10. Synapse Biomedical Inc. Chapter 9. Research Process 9.1. Research Process 9.1.1. Data Mining 9.1.2. Analysis 9.1.3. Market Estimation 9.1.4. Validation 9.1.5. Publishing 9.2. Research Attributes 9.3. Research Assumption
Global Neuromodulation market is valued at approximately USD 5.78 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 8.8 % over the forecast period 2020-2027. Increased life expectancy has resulted in a substantial rise in the number of the elderly population. Alzheimer’s disease, Parkinson’s disease, stroke, and other neurodegenerative diseases are all related to ageing. Neurological disorders are a major social and economic burden that presents a severe danger to public health. The rapid ageing of the population is a global epidemic with significant consequences in a number of areas, including health. According to the 2017 Revision of the World Population Prospects, the number of people aged 60 and up will more than double by 2050, from 962 million in 2017 to 2.1 billion. During this time frame, the oldest section of the population, people over 80 years old, is projected to triple, from 137 million in 2017 to 425 million in 2050. Given the strong association between age and the prevalence of certain neurological diseases, neurology is a medical specialty that would be especially impacted by these dramatic demographic changes. The increase in elderly people will be followed by an increase in the number of patients suffering from neurological disorders. Additionally, by 2030, it is estimated that the overall average number of stroke cases will have increased by 55 percent, with the bulk of these cases involving elderly people (65% in people 75 years old versus 25% in those 75 years old). Thus, rising ageing population across different economies is expected to boost the market growth over the forecast period. However, high cost of advertisement may hamper small business to enter promotional market and, may impede market growth over the forecast period of 2020-2027.
The regional analysis of the global Neuromodulation market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is projected to lead the global neuromodulation market in 2019 and retain a substantial market share over the forecast period (2020-2027). The rising incidence of spinal cord injury is expected to drive business expansion. Whereas Asia Pacific is also anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027, due to rise in neurological disorders, especially cerebrovascular and neurodegenerative disorders. The ageing population, as well as increased understanding and diagnosis among doctors and patients in Asia, would lead to an increase in neurodegenerative disorders.
Major market player included in this report are:
Boston Scientific Corporation
Synapse biomedical Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027.
Target Audience of the Global Neuromodulation market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Value-Added Resellers (VARs)
Third-party knowledge providers